Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
The Curtis and Elizabeth Anderson Cancer Institute (ACI) at Memorial University Medical Center, is a cancer center in Savannah, Georgia. Memorial Health is accredited by the Commission on Cancer of the American College of Surgeons as a Teaching Hospital Cancer Program. The center is a recipient of the Georgia Cancer Coalition Distinguished Cancer Scholars Award, which supports leaders who are engaged in the most promising areas of cancer research. Memorial Health is a member of the Georgia CORE Research Network, a statewide network of academic and community-based oncologists and researchers and a member of the Georgia CORE Gynecologic Oncology Group Consortium. The center consists of 32 physicians, including two radiation oncologists. Memorial Health offers a state-of-the-art research laboratory, leading-edge technology and compassionate support programs. They offer the following services: community support groups, educational programs, insurance assistance, resource room, oncology interdisciplinary care, coordination team, oncology social workers, patient advocacy, support line, wellness services, spiritual care and pediatric services.
Treatment Sites in Georgia
Clinical Trials in Georgia
A Study of Combination Chemotherapy for Patients with Newly Diagnosed DAWT and Relapsed FHWT
Cancer Type: Brain Tumor, Unknown Primary, Wilms Tumor
A Study to Compare Blinatumomab Alone to Blinatumomab with Nivolumab in Patients Diagnosed with First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Cancer Type: Hematopoietic Malignancies, Leukemia, Unknown Primary
A Study to Compare Standard Chemotherapy to Therapy with CPX-351 and/or Gilteritinib for Patients with Newly Diagnosed AML with or without FLT3 Mutations
Cancer Type: Leukemia
Dabrafenib Combined with Trametinib after Radiation Therapy in Treating Patients with Newly-Diagnosed High-Grade Glioma
Cancer Type: Brain & Spinal Cord Tumor, Brain Tumor
Imatinib Mesylate and Combination Chemotherapy in Treating Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Cancer Type: Leukemia
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients with High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Cancer Type: Leukemia, Testicular Cancer
Inotuzumab Ozogamicin in Treating Younger Patients with B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Cancer Type: Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
Intraoperative Radiation Therapy in Treating Patients with Breast Cancer Undergoing Breast-Conserving Surgery
Cancer Type: Breast Cancer
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab with or without Eflornithine in Treating Patients with Relapsed or Refractory Neuroblastoma
Cancer Type: Neuroblastoma
Pilot Study of Neuropsychological and Behavioral Assessment in Children With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)
Cancer Type: Brain Tumor
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients with Newly Diagnosed WNT-Driven Medulloblastoma
Cancer Type: Brain & Spinal Cord Tumor, Brain Tumor, Unknown Primary
Research Study of Clinical, Genetic, and Biological Factors as Prognostic Values in Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
Cancer Type: Neuroblastoma
Study of Renal Tumors in Pediatric Patients
Cancer Type: Kidney Cancer
Sublobar Resection or Stereotactic Ablative Radiotherapy in Treating Patients with Stage I Non-small Cell Lung Cancer, The STABLE-MATES Trial
Cancer Type: Lung Cancer, Unknown Primary
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Cancer Type: Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Wilms Tumor
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People with High-Risk Neuroblastoma (NBL)
Cancer Type: Neuroblastoma, Neurologocal Tumor
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please
contact us.